Compositions for improving cell viability and methods of use thereof
This invention relates to methods and compositions for use improving cell viability, particularly neural cell viability, and more particularly to methods and compositions for use improving cell viability by reducing reactive oxygen metabolite-mediated oxidative damage in a cell, regulating redox homeostasis in a cell, or reducing mitochondrial dysfunction in a cell. The invention further relates to the administration of the bile acid tauroursodeoxycholic acid (TUDCA) in combination with phenylbutyric Acid (PBA) to improve cell viability, and treat at least one symptom associated with, prevent the time of onset of, or slow the development of a disease related to oxidative stress.
1. A method of treating a neurodegenerative disease, the method comprising administering to a subject
about 10 mg/kg to about 50 mg/kg of body weight of tauroursodeoxycholic acid (TUDCA), or a pharmaceutically acceptable salt thereof; and
about 10 mg/kg to about 400 mg/kg of body weight of 4-phenylbutyric acid (4-PBA), or a pharmaceutically acceptable salt thereof,
wherein the TUDCA and 4-PBA are administered in an amount sufficient to treat the neurodegenerative disease.
2. The method of claim 1 , wherein in the subject is a mammal.
3. The method of claim 1 , wherein in the subject is human.
4. The method of claim 1 , wherein the neurodegenerative disease is selected from the group consisting of Multiple Sclerosis (MS), Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), stroke, Pick's Disease, Multi-Infarct Dementia, Creutzfeldt-Jakob's Disease, Dementia with Lewy bodies, Mixed dementia and Frontotemporal dementia.
5. The method of claim 1 , comprising administering to a subject about 10 mg/kg to about 30 mg/kg of body weight of tauroursodeoxycholic acid (TUDCA).
6. The method of claim 1 , comprising administering to a subject about 10 mg/kg to about 100 mg/kg of body weight 4-PBA.
7. The method of claim 1 , comprising administering to a subject about 30 mg/kg to about 100 mg/kg of body weight 4-PBA.
8. The method of claim 1 , wherein the tauroursodeoxycholic acid (TUDCA) and 4-PBA are administered separately.
9. The method of claim 1 , wherein the tauroursodeoxycholic acid (TUDCA) and 4-PBA are administered once a day, twice a day, or three times a day.
10. The method of claim 1 , wherein the neurodegenerative disease is caused by oxidative stress or mitochondrial dysfunction.
11. The method of claim 1 , wherein the TUDCA and 4-PBA are administered in an amount sufficient to reduce reactive oxygen metabolite-mediated oxidative damage in a cell of the subject.
12. The method of claim 11 , wherein the reactive oxygen metabolite-mediated oxidative damage is hydrogen peroxide (H2O2) mediated damage.
13. The method of claim 1 , wherein the TUDCA and 4-PBA are administered in an amount sufficient to promote redox homeostasis in a cell of the subject.
14. The method of claim 1 , wherein the TUDCA and 4-PBA are administered in an amount sufficient to reduce mitochondrial dysfunction in a cell of the subject.